Shadoud Lubana, Almahmoud Iyad, Jarraud Sophie, Etienne Jérôme, Larrat Sylvie, Schwebel Carole, Timsit Jean-François, Schneider Dominique, Maurin Max
Univ. Grenoble Alpes, Laboratoire Adaptation et Pathogénie des Microorganismes (LAPM), F-38000 Grenoble, France ; Centre National de la Recherche Scientifique (CNRS), LAPM, F-38000 Grenoble, France ; Centre Hospitalier Universitaire (CHU) Grenoble, Institut de Biologie et de Pathologie, Grenoble, France.
Université Lyon 1, Centre International de Recherche en Infectiologie, Lyon, France ; CNRS UMR5308, Ecoles Normales Supérieures (ENS), Lyon, France ; Institut National de la Santé et de la Recherche Médicale (INSERM) U1111, Lyon, France ; Centre National de Référence des Legionella , Centre de Biologie Est, Hospices Civils de Lyon, Lyon, France.
EBioMedicine. 2015 Jul 17;2(9):1179-85. doi: 10.1016/j.ebiom.2015.07.018. eCollection 2015 Sep.
Infectious diseases are the leading cause of human morbidity and mortality worldwide. One dramatic issue is the emergence of microbial resistance to antibiotics which is a major public health concern. Surprisingly however, such in vivo adaptive ability has not been reported yet for many intracellular human bacterial pathogens such as Legionella pneumophila.
We examined 82 unrelated patients with Legionnaire's disease from which 139 respiratory specimens were sampled during hospitalization and antibiotic therapy. We both developed a real time PCR assay and used deep-sequencing approaches to detect antibiotic resistance mutations in L. pneumophila and follow their selection and fate in these samples.
We identified the in vivo selection of fluoroquinolone resistance mutations in L. pneumophila in two infected patients treated with these antibiotics. By investigating the mutational dynamics in patients, we showed that antibiotic resistance occurred during hospitalization most likely after fluoroquinolone treatment.
In vivo selection of antibiotic resistances in L. pneumophila may be associated with treatment failures and poor prognosis. This hidden resistance must be carefully considered in the therapeutic management of legionellosis patients and in the control of the gradual loss of effectiveness of antibiotics.
传染病是全球人类发病和死亡的主要原因。一个严峻的问题是微生物对抗生素产生耐药性,这是一个重大的公共卫生问题。然而,令人惊讶的是,许多细胞内人类细菌病原体,如嗜肺军团菌,尚未报道过这种体内适应能力。
我们检查了82例患军团病的不相关患者,在住院和抗生素治疗期间从他们身上采集了139份呼吸道标本。我们开发了一种实时PCR检测方法,并使用深度测序方法来检测嗜肺军团菌中的抗生素耐药性突变,并追踪这些样本中突变的选择和演变情况。
我们在两名接受这些抗生素治疗的感染患者中发现了嗜肺军团菌对氟喹诺酮耐药性突变的体内选择。通过研究患者的突变动态,我们发现抗生素耐药性在住院期间出现,很可能是在氟喹诺酮治疗之后。
嗜肺军团菌体内抗生素耐药性的选择可能与治疗失败和预后不良有关。在军团病患者的治疗管理以及对抗生素有效性逐渐丧失的控制中,必须认真考虑这种隐藏的耐药性。